Market
Story
FDA Approves Eli Lilly's Zepbound (Tirzepatide) as First Drug for Sleep Apnea
Dec 20, 2024, 09:37 PM
On December 20, the FDA approved Eli Lilly's weight-loss drug Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity, affecting approximately 39 million U.S. adults. Clinical trials showed that patients taking Zepbound experienced at least 25 fewer breathing interruptions per hour, and up to 50% had zero symptoms after one year of treatment. This landmark approval offers a new treatment option for those suffering from obstructive sleep apnea, a serious sleep-related breathing disorder.
View original story
Similar markets
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Other • 25%
AstraZeneca's Roxadustat • 25%
Pfizer's Danuglipron • 25%
Novo Nordisk's Wegovy • 25%
More than 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
Zepbound • 25%
CPAP devices • 25%
Other treatments • 25%
Alternative medications • 25%
No • 50%
Yes • 50%
1 new competitor • 25%
3 or more new competitors • 25%
No new competitors • 25%
2 new competitors • 25%
10% to 20% • 25%
More than 30% • 25%
20% to 30% • 25%
Less than 10% • 25%
No • 50%
Yes • 50%
100,000 to 200,000 • 25%
200,001 to 300,000 • 25%
More than 300,000 • 25%
Less than 100,000 • 25%
3 or more major competitors • 25%
2 major competitors • 25%
1 major competitor • 25%
No major competitors • 25%